Genomma Lab Internacional Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 1,665

Employees

  • Stock Symbol
  • LABB

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $0.82
  • (As of Friday Closing)

Genomma Lab Internacional General Information

Description

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Avenida Antonio Dovalí Jaime, number 70, tower C, floor 2, office A
  • Colonia Santa Fe. CP
  • Mexico City, 01210
  • Mexico
+52
Primary Industry
Personal Products
Other Industries
Pharmaceuticals
Stock Exchange
MEX
Vertical(s)
Corporate Office
  • Avenida Antonio Dovalí Jaime, number 70, tower C, floor 2, office A
  • Colonia Santa Fe. CP
  • Mexico City, 01210
  • Mexico
+52

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genomma Lab Internacional Stock Performance

As of 13-Nov-2026, Genomma Lab Internacional’s stock price is $0.82. Its current market cap is $803M with 978M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.82 $0.84 $0.68 - $1.13 $803M 978M 3.89M $0.10

Genomma Lab Internacional Financials Summary

As of 30-Sep-2026, Genomma Lab Internacional has a trailing 12-month revenue of $969M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 973,409 1,243,164 1,389,110 1,073,789
Revenue 968,969 912,472 1,015,638 927,396
EBITDA 190,498 181,836 220,102 147,602
Net Income 96,528 83,958 81,500 57,800
Total Assets 1,402,774 1,315,496 1,114,011 1,218,802
Total Debt 443,436 423,536 313,987 367,419
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genomma Lab Internacional Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genomma Lab Internacional‘s full profile, request access.

Request a free trial

Genomma Lab Internacional Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improv
Personal Products
Mexico City, Mexico
1,665 As of 2025

Mumbai, India
 

Yilan City, Taiwan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genomma Lab Internacional Competitors (20)

One of Genomma Lab Internacional’s 20 competitors is Glenmark Pharmaceuticals, a Corporation company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Glenmark Pharmaceuticals Corporation Mumbai, India
SynCore Biotechnology Company Corporation Yilan City, Taiwan
Shionogi Corporation Osaka, Japan
Cipla Corporation Mumbai, India
Novavax Corporation Gaithersburg, MD
You’re viewing 5 of 20 competitors. Get the full list »

Genomma Lab Internacional Patents

Genomma Lab Internacional Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2013028049-A2 Composition for the percutaneous administration of active compounds providing a suitable treatment for androgenetic alopecia Inactive 25-Aug-2011
WO-2013028049-A3 Composition for the percutaneous administration of active compounds providing a suitable treatment for androgenetic alopecia Inactive 25-Aug-2011

Genomma Lab Internacional Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genomma Lab Internacional Investments & Acquisitions (6)

Genomma Lab Internacional’s most recent deal was a Corporate Asset Purchase with Isa Laboratorios (Treg Brand). The deal was made on 25-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Isa Laboratorios (Treg Brand) 25-Jul-2024 Corporate Asset Purchase Buildings and Property
Suero Oral 24-Jul-2024 Merger/Acquisition Beverages
Joint Venture (Genomma Lab Internacional/Oravax Medical) 18-Nov-2021 Joint Venture Drug Discovery
Dr. Reddy's Laboratories (Bufferin Brand) 14-Jun-2018 Corporate Asset Purchase Buildings and Property
Sheffield Pharmaceuticals (Cheracol D and Rose Milk) 14-Jun-2018 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Genomma Lab Internacional ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

28.06 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Genomma Lab Internacional’s complete esg history, request access »

Genomma Lab Internacional Exits (1)

Genomma Lab Internacional’s most recent exit was on 30-Jun-2014 from Marzam. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Marzam 30-Jun-2014 Completed
To view Genomma Lab Internacional’s complete exits history, request access »

Genomma Lab Internacional Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Suero Oral Miami, FL 1999

Genomma Lab Internacional FAQs

  • When was Genomma Lab Internacional founded?

    Genomma Lab Internacional was founded in 1996.

  • Where is Genomma Lab Internacional headquartered?

    Genomma Lab Internacional is headquartered in Mexico City, Mexico.

  • What is the size of Genomma Lab Internacional?

    Genomma Lab Internacional has 1,665 total employees.

  • What industry is Genomma Lab Internacional in?

    Genomma Lab Internacional’s primary industry is Personal Products.

  • Is Genomma Lab Internacional a private or public company?

    Genomma Lab Internacional is a Public company.

  • What is Genomma Lab Internacional’s stock symbol?

    The ticker symbol for Genomma Lab Internacional is LABB.

  • What is the current stock price of Genomma Lab Internacional?

    As of 13-Nov-2026 the stock price of Genomma Lab Internacional is $0.82.

  • What is the current market cap of Genomma Lab Internacional?

    The current market capitalization of Genomma Lab Internacional is $803M.

  • What is Genomma Lab Internacional’s current revenue?

    The trailing twelve month revenue for Genomma Lab Internacional is $969M.

  • Who are Genomma Lab Internacional’s competitors?

    Glenmark Pharmaceuticals, SynCore Biotechnology Company, Shionogi, Cipla, and Novavax are some of the 20 competitors of Genomma Lab Internacional.

  • What is Genomma Lab Internacional’s annual earnings per share (EPS)?

    Genomma Lab Internacional’s EPS for 12 months was $0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process